title: Clarification of enrolled subjects in tolvaptan HF trials.
authors.affiliation: Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Rockville, Maryland, USA.
authors.forename: J
authors.initials: J
authors.lastname: Blais
authors.affiliation: US Medical Affairs, Otsuka America Pharmaceutical, Princeton, New Jersey, USA.
authors.forename: J
authors.initials: J
authors.lastname: Chiodo
authors.affiliation: US Medical Affairs, Otsuka America Pharmaceutical, Princeton, New Jersey, USA.
authors.forename: K
authors.initials: K
authors.lastname: Friend
authors.affiliation: Clinical Pharmacology, Otsuka Pharmaceutical Development & Commercialization, Rockville, Maryland, USA.
authors.forename: S
authors.initials: S
authors.lastname: Shoaf
mesh_terms: D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000037:antagonists & inhibitors*; D015195:Drug Design; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin